|
|
|
| Immunological Activity of a Chimeric Protein Carrying an Epitope of Type 2 Poliovirus on the VP6 of Rotavirus as a Vector |
| WANG Jing1, XIA Wen-yue1, PAN Xiao-xia2, ZHAO Bing-xin1, TENG Yu-mei1, LI Chuan-yin1, YANG Xiao-zhou1, WEN Yu-ling1, CHEN Yuan-ding1 |
1. Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research and Development on Severe Infectious Diseases, Kunming 650118, China;
2. Key Laboratory of Chemistry in Ethnic Medicinal Resources, State Ethnic Affairs Commission and Ministry of Education, Yunnan Minzu University, Kunming 650500, China |
|
|
|
Abstract Objective:To evaluate immunological activity of chimeric protein carrying one PV2 antigenic epitope on rotavirus VP6. Methods:one chimeric protein was constructed by inserting an epitope derived from neutralizing antigenic sites 1 of PV2 in rotavirus VP6 as a vector through gene cloning and recombination; the chimeric protein was expressed in E.coli cells and detected by Western blot,immunofluorescence assay and neutralization test. Results:The chimeric protein was favorably constructed and expressed in E.coli cells efficiently. Antibodies induced in inoculated guinea pigs by the chimeric protein could both neutralize the infection of RV and PV2 in vitro. Conclusion:The constructed chimeric protein possesses dual immunogenicity and can elicit production of antibodies in immunized guinea pigs which can protect infection of RV in MA104 cells and PV in Vero cells. The results are valuable for development of new RV/PV2 bivalent vaccine.
|
|
Received: 23 May 2016
Published: 25 August 2016
|
|
|
|
Cite this article:
WANG Jing, XIA Wen-yue, PAN Xiao-xia, ZHAO Bing-xin, TENG Yu-mei, LI Chuan-yin, YANG Xiao-zhou, WEN Yu-ling, CHEN Yuan-ding. Immunological Activity of a Chimeric Protein Carrying an Epitope of Type 2 Poliovirus on the VP6 of Rotavirus as a Vector. China Biotechnology, 2016, 36(8): 1-8.
URL:
https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20160801 OR https://manu60.magtech.com.cn/biotech/Y2016/V36/I8/1
|
|
|
| [1] Kapikian A Z, Flores J, Hoshino Y, et al. Rotavirus:the major etiologic agent of severe infantile diarrhea may be controllable by a "Jennerian" approach to vaccination. J Infect Dis, 1986, 153(5):815-822.
[2] Tate J E, Burton A H, Boschi-Pinto C, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes:a systematic review and meta-analysis. Lancet Infect Dis, 2012,12(2):136-141.
[3] Teng Y, Zhao B, Pan X, et al. A new rotavirus VP6-based foreign epitope presenting vector and immunoreactivity of VP4 epitope chimeric proteins. Viral Immunol, 2014, 27(3):96-104.
[4] Tang B, Gilbert J M, Matsui S M, et al. Comparison of the rotavirus gene 6 from different species by sequence analysis and localization of subgroup-specific epitopes using site-directed mutagenesis. Virology, 1997, 237(1):89-96.
[5] Matthijnssens J, Otto P H, Ciarlet M, et al. VP6-sequence-based cutoff values as a criterion for rotavirus species demarcation. Arch Virol, 2012, 157(6):1177-1182.
[6] Badillo-Godinez O, Gutierrez-Xicotencatl L, Plett-Torres T, et al. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice. Vaccine, 2015,33(35):4228-4237.
[7] Zhao B, Pan X, Teng Y, et al. Rotavirus VP7 epitope chimeric proteins elicit cross-immunoreactivity in guinea pigs. Virol Sin, 2015, 30(5):363-370.
[8] Wimmer E, Hellen C U, Cao X. Genetics of poliovirus. Annu Rev Genet, 1993, 27:353-436.
[9] Hogle J M, Filman D J. The antigenic structure of poliovirus. Philos Trans R Soc Lond B Biol Sci, 1989,323(1217):467-478.
[10] Rotavirus vaccines. WHO position paper-January 2013. Wkly Epidemiol Rec, 2013, 88:49-64.
[11] Desselberger U, Manktelow E, Li W, et al. Rotaviruses and rotavirus vaccines. Br Med Bull, 2009, 90(1):37-51.
[12] Vesikari T. Success of rotavirus vaccination in Africa:good news and remaining questions. Lancet Glob Health, 2016, 4:e76-77.
[13] Dunn G, Klapsa D, Wilton T, et al. Twenty-eight years of poliovirus replication in an immunodeficient individual:Impact on the global polio eradication initiative. PLoS Pathog, 2015, 11(8):e1005114.
[14] Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 1976, 72:248-254.
[15] Glass R I, Bresee J S, Parashar U, et al. Rotavirus vaccines:past, present, and future. Arch Pediatr, 2005, 12(6):844-847.
[16] Cherian T, Wang S, Mantel C. Rotavirus vaccines in developing countries:the potential impact, implementation challenges, and remaining questions. Vaccine, 2012, 30(Suppl 1):3-6.
[17] Shui I M, Baggs J, Patel M, et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA, 2012, 307(6):598-604.
[18] Buttery J, Danchin M H, Lee K J, et al. Intussusception following rotavirus vaccinead ministration:post-marketing surveillance in the National Immunization Program in Australia. Vaccine, 2011, 29(16):3061-3066.
[19] Wilder-Smith A, Leong W Y, Lopez L F, et al. Potential for international spread of wild poliovirus via travelers. BMC Med, 2015, 13(1):133.
[20] Liang X, Zhang Y, Xu W, et al. An outbreak of poliomyelitis caused by type1 vaccine-derived poliovirus in China. J Infect Dis, 2006, 194:545-551. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
